|

Adenosine A2B Receptor Antagonist PBF-1129 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: A2BR Antagonist PBF-1129, PBF 1129, PBF-1129, PBF1129

Pipeline

Phase 1: 1

Top Sponsors

  • Dwight Owen1

Indications

  • Recurrent Lung Non-Small Cell Carcinoma1
  • Stage IVB Lung Cancer AJCC v81
  • Stage IVA Lung Cancer AJCC v81
  • Stage IV Lung Cancer AJCC v81
  • Metastatic Lung Non-Small Cell Carcinoma1

Columbus, Ohio1 trial

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.